The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...

Cognition Therapeutics shares surged after the clinical-stage company said it completed the end-of-Phase 2 meeting with the Food and Drug Administration for its zervimesine drug. Shares were up 30% at ...

Sara Penuela Rodriguez (left), an interdisciplinary neuroscience doctoral student, administers infrared laser light therapy ...